Cell culture-derived flu vaccine: Present and future.

Hum Vaccin Immunother

b Servicio Microbiología, Hospital Universitario Rio Hortega, Valladolid , Spain.

Published: April 2019

The benefit of influenza vaccines is difficult to estimate due to the complexity of accurately assessing the burden of influenza. To improve the efficacy of influenza vaccines, vaccine manufacturers have developed quadrivalent influenza vaccine (QIV) formulations for seasonal vaccination by including both influenza B lineages. Three parallel approaches for producing influenza vaccines are attracting the interest of many vaccine manufacturing companies. The first and oldest is the conventional egg-derived influenza vaccine, which is used by the current licensed influenza vaccines. The second approach is a cell culture-derived influenza vaccine, and the third and most recent is synthetic vaccines. Here, we analyze the difficulties with vaccines production in eggs and compare this to cell culture-derived influenza vaccines and discuss the future of cell culture-derived QIVs.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6149758PMC
http://dx.doi.org/10.1080/21645515.2018.1460297DOI Listing

Publication Analysis

Top Keywords

influenza vaccines
20
cell culture-derived
16
influenza vaccine
12
influenza
10
culture-derived influenza
8
vaccines
7
vaccine
6
cell
4
culture-derived flu
4
flu vaccine
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!